Synthesis and Infarction-Limiting Properties of Peptide Agonists of Opioid Receptors
- Authors: Tsibul’nikov S.Y.1, Mukhomedzyanov A.V.1, Maslov L.N.1, Ovchinnikov M.V.2, Sidorova M.V.2, Kudryavtseva E.V.2, Bushov Y.V.3, Lishmanov Y.B.1, Khaliulin I.4
 - 
							Affiliations: 
							
- Cardiology Research Institute, Tomsk National Research Medical Center
 - Peptide Synthesis Company
 - Tomsk State University
 - University of Bristol
 
 - Issue: Vol 52, No 4 (2018)
 - Pages: 291-293
 - Section: Search for New Drugs
 - URL: https://journals.rcsi.science/0091-150X/article/view/245142
 - DOI: https://doi.org/10.1007/s11094-018-1808-3
 - ID: 245142
 
Cite item
Abstract
Three structurally different peptide agonists of opioid receptors, i.e., gludalan, deltolei, and dalargin, were synthesized and assessed for infarction-limiting effects in rats with coronary occlusion (45 min) and reperfusion (2 h). The opioid peptides dalargin and gludalan (0.1 mg/kg) and deltolei (0.03, 0.1, and 0.2 mg/kg) were injected 5 min before reperfusion. It was found that gludalan and deltolei at a dose of 0.1 mg/kg decreased the ratio of infarction size to the area at risk (IS/AAR) whereas dalargin did not affect the IS. The infarction-limiting effect of deltolei disappeared if the peptide dose was decreased (0.03 mg/kg) or increased (0.2 mg/kg). The opioid receptor antagonists naltrexone (5 mg/kg) or naloxone methiodide (5 mg/kg), which does not penetrate the blood—brain barrier, eliminated the infarction-limiting effect of gludalan.
Keywords
About the authors
S. Yu. Tsibul’nikov
Cardiology Research Institute, Tomsk National Research Medical Center
														Email: chem@folium.ru
				                					                																			                												                	Russian Federation, 							Tomsk, 634009						
A. V. Mukhomedzyanov
Cardiology Research Institute, Tomsk National Research Medical Center
														Email: chem@folium.ru
				                					                																			                												                	Russian Federation, 							Tomsk, 634009						
L. N. Maslov
Cardiology Research Institute, Tomsk National Research Medical Center
														Email: chem@folium.ru
				                					                																			                												                	Russian Federation, 							Tomsk, 634009						
M. V. Ovchinnikov
Peptide Synthesis Company
														Email: chem@folium.ru
				                					                																			                												                	Russian Federation, 							Moscow, 121552						
M. V. Sidorova
Peptide Synthesis Company
														Email: chem@folium.ru
				                					                																			                												                	Russian Federation, 							Moscow, 121552						
E. V. Kudryavtseva
Peptide Synthesis Company
														Email: chem@folium.ru
				                					                																			                												                	Russian Federation, 							Moscow, 121552						
Yu. V. Bushov
Tomsk State University
														Email: chem@folium.ru
				                					                																			                												                	Russian Federation, 							Tomsk, 634050						
Yu. B. Lishmanov
Cardiology Research Institute, Tomsk National Research Medical Center
														Email: chem@folium.ru
				                					                																			                												                	Russian Federation, 							Tomsk, 634009						
I. Khaliulin
University of Bristol
														Email: chem@folium.ru
				                					                																			                												                	United Kingdom, 							Bristol, BS8 1TH						
Supplementary files
				
			
					
						
						
						
						
				